跳至主要内容
临床试验/NCT04004403
NCT04004403已完成不适用

Alternate Day Fasting Combined With Exercise for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD)

University of Illinois at Chicago2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2019年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
2
主要终点
Change in Hepatic Steatosis

研究概览

简要总结

Approximately 65% of obese individuals have non-alcoholic fatty liver disease (NAFLD), and this condition is strongly related to the development of insulin resistance and diabetes. Innovative lifestyle strategies to treat NAFLD are critically needed. The proposed research will demonstrate that alternate day fasting (ADF) combined with exercise is an effective non-pharmacological therapy to treat NAFLD.

详细描述

Nonalcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver (not resulting from excessive alcohol consumption). Approximately 65% of obese individuals have NAFLD, and this condition is strongly related to the development of insulin resistance and type 2 diabetes. While certain pharmacological agents have been shown to reduce liver fat (i.e. thiazolidinediones), there is mounting concern regarding the safety and weight-gaining effects of these compounds. In light of this, recent research has focused on non-pharmacological lifestyle therapies to reduce hepatic steatosis, such as daily calorie restriction combined with aerobic exercise. Evidence from clinical trials suggest that this combination is an effective lifestyle therapy improve liver fat content and hepatic insulin sensitivity.

More recently, it's been shown that intermittent fasting may produce even greater improvements in hepatic steatosis and hepatic insulin sensitivity, when compared to conventional calorie restriction. For instance, intrahepatic lipid accumulation was lower and insulin sensitivity was higher in mice fasted every other day, when compared to mice who were energy restricted every day. Moreover, data from human trials show that adults with obesity experience greater decreases in insulin and insulin resistance with intermittent fasting versus daily restriction. These findings suggest that intermittent fasting may be a more effective diet therapy to reduce hepatic steatosis and improve insulin sensitivity, when compared to daily calorie restriction. Although these findings are very promising, these data still require confirmation by a randomized controlled clinical trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Change in Hepatic Steatosis

时间窗: Change from week 1 to week 12

Hepatic steatosis will be measured by magnetic resonance imaging (MRI-PDFF)

次要结局

  • Change in Alanine Aminotransferase (ALT)(Change from week 1 to week 12)
  • Change in Aspartate Aminotransferase (AST)(Change from week 1 to week 12)
  • Change in HbA1c(Change from week 1 to week 12)
  • Change in Body Weight(Change from week 1 to week 12)
  • Change in Alanine Aminotransferase (ALT)(Change from week 1 to week 12)
  • Change in Aspartate Aminotransferase (AST)(Change from week 1 to week 12)
  • Change in Fasting Glucose(Change from week 1 to week 12)
  • Change in Fasting Insulin(Change from week 1 to week 12)
  • Change in Insulin Resistance(Change from week 1 to week 12)
  • Change in HbA1c(Change from week 1 to week 12)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Krista Varady

Professor of Nutrition

University of Illinois at Chicago

研究点 (2)

Loading locations...

相似试验